Novo Nordisk A/S

NOVO B

DK0062498333

Pharmaceuticals

Market Closed - Nasdaq Copenhagen Other stock markets 16:20:00 16/03/2026 GMT			5-day change	1st Jan Change
248.30 ^DKK	+0.51%		-2.44%	-23.66%

03-16	Genentech CEO says aiming for tolerable, affordable obesity drugs	RE
03-16	Structure's obesity pill shows up to 16.3% weight loss in study	RE

Novo Nordisk CEO: Medicare Opens Door to 15 Million New Patients in the U.S.

Published on 02/12/2026 at 09:22 am GMT

Finwire - Translated by Marketscreener - See original

NOVO NORDISK A/S

+0.51%

Danish pharmaceutical company Novo Nordisk's CEO, Mike Doustdar, states that the company aims to reach around 15 million new patients when Medicare begins to cover obesity drugs later in 2026, according to CNBC.

According to the CEO, Medicare covers approximately 67 million Americans, and expanded reimbursement, together with the launch of a new obesity pill, is expected to gradually increase prescription volumes and counteract lower prices in the U.S. following the company's agreement with authorities.

At the same time, Doustdar notes that the rollout will take place in stages and that negotiations are ongoing regarding the exact timing of when the reimbursement will take effect.

Latest news about Novo Nordisk A/S

03-16	Genentech CEO says aiming for tolerable, affordable obesity drugs	RE
03-16	Structure's obesity pill shows up to 16.3% weight loss in study	RE
03-16	Lannebo Norden dipped 0.5 percent in February ? reintroduces SCA to the portfolio	FW
03-16	Bråse buys back into Novo Nordisk - Afv	FW
03-14	How are different indices influenced?
03-13	Form Health Joins Lilly Employer Connect Platform	CI
03-13	Viatris' Mylan Drops Claims Disputing Novo's Patent-Infringement Suit	MT
03-13	Health Rounds: Eliquis proves safer than Xarelto for patients with deep blood clots	RE
03-12	Unifor Local 27 ratifies three-year agreement with Catalent	RE
03-12	Viatris' Mylan Drops Claims Disputing Novo's Patent-Infringement Suit	MT
03-12	Viatris' Mylan Drops Claims Disputing Novo's Patent-Infringement Suit	MT
03-12	Berenberg cuts Novo Nordisk price target on Cagrisema outlook - BN	FW
03-12	Tellus Midas declined 1.30 percent in February - increased cash position	FW
03-12	Novo Nordisk Price Target Cut as Berenberg Expects Lower CagriSema Sales Amid Recent Clinical Data	MT
03-12	Lilly finds impurity in compounded version of its weight-loss drug, warns of health risks	RE

Chart Novo Nordisk A/S

Duration

Period

NOVO B: Dynamic Chart

Company Profile

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (93.7%); - rare disease treatment products (6.3%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe and Canada (21.4%), the United States (56%), Latin America/Middle East/Africa (9.9%), China/Hong Kong/Taiwan (6%), Asia/Pacific (6.7%).

Employees

69,150

Sector

Pharmaceuticals

Calendar

03-27 - Ex-dividend date - 7.95 DKK

More about the company